{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:45:11Z","timestamp":1789487111663,"version":"build-2803163510"},"reference-count":151,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-25431554"],"award-info":[{"award-number":["RS-2025-25431554"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02316334"],"award-info":[{"award-number":["RS-2025-02316334"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"award":["RS-2025-25431554"],"award-info":[{"award-number":["RS-2025-25431554"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["RS-2025-02316334"],"award-info":[{"award-number":["RS-2025-02316334"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Despite rapid advances in anticancer therapy, cancer incidence and mortality remain substantial worldwide. Although immune checkpoint inhibitors (ICIs), including anti-PD-1\/PD-L1 and anti-CTLA-4 therapies, have transformed cancer treatment by harnessing host antitumor immunity, their efficacy remains limited to a subset of patients, largely because of the complexity of the tumor microenvironment. This review examines drug-induced immunogenic cell death (ICD) and drug-induced senescence as complementary strategies for overcoming these limitations and enhancing immunotherapeutic responses. We further highlight evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration. This dose- and time-dependent relationship suggests that the therapeutic application of the same agent may require optimization according to the patient\u2019s condition and tumor stage. Collectively, this review provides an integrated perspective on the selective use of ICD and senescence induction to enhance antitumor immunity, improve therapeutic outcomes, and potentiate synergistic responses to existing ICIs.<\/jats:p>","DOI":"10.3390\/life16091536","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:33:42Z","timestamp":1789479222000},"page":"1536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Seong-Ah","family":"Shin","sequence":"first","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonsu","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyeon","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-0847","authenticated-orcid":false,"given":"Hyun Ho","family":"Park","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chung Ang University, Seoul 06974, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Sup","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Liu, C., Yang, M., Zhang, D., Chen, M., and Zhu, D. (2022). Clinical cancer immunotherapy: Current progress and prospects. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.961805"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., and Depil, S. (2019). Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00168"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning Cold into Hot: Firing up the Tumor Microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11795549221120708","DOI":"10.1177\/11795549221120708","article-title":"Igniting Hope for Tumor Immunotherapy: Promoting the \u201cHot and Cold\u201d Tumor Transition","volume":"16","author":"Wei","year":"2022","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5483\/BMBRep.2014.47.2.005","article-title":"Exploiting tumor cell senescence in anticancer therapy","volume":"47","author":"Lee","year":"2014","journal-title":"BMB Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","article-title":"Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity","volume":"13","author":"Marin","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bezu, L., Gomes-da-Silva, L.C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., and Kroemer, G. (2015). Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00187"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/ol.2016.4175","article-title":"Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma","volume":"11","author":"Kawano","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s40425-019-0826-3","article-title":"Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine","volume":"7","author":"Turubanova","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zhu, M., Yang, M., Zhang, J., Yin, Y., Fan, X., Zhang, Y., Qin, S., Zhang, H., and Yu, F. (2021). Immunogenic cell death induction by ionizing radiation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.705361"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5483\/BMBRep.2023-0024","article-title":"Immunogenic cell death in cancer immunotherapy","volume":"56","author":"Choi","year":"2023","journal-title":"BMB Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kielbik, M., Szulc-Kielbik, I., and Klink, M. (2021). Calreticulin\u2014Multifunctional chaperone in immunogenic cell death: Potential significance as a prognostic biomarker in ovarian cancer patients. Cells, 10.","DOI":"10.3390\/cells10010130"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-007-0214-1","article-title":"Molecular determinants of immunogenic cell death: Surface exposure of calreticulin makes the difference","volume":"85","author":"Chaput","year":"2007","journal-title":"J. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/cdd.2016.5","article-title":"Immunogenic versus tolerogenic phagocytosis during anticancer therapy: Mechanisms and clinical translation","volume":"23","author":"Garg","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_31","first-page":"47","article-title":"Immunogenic cell death: A step ahead of autophagy in cancer therapy","volume":"3","author":"Gupta","year":"2021","journal-title":"J. Cancer Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Serrano-del Valle, A., Anel, A., Naval, J., and Marzo, I. (2019). Immunogenic cell death and immunotherapy of multiple myeloma. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00050"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1667743","DOI":"10.1080\/2162402X.2019.1667743","article-title":"Immunogenic cell death in a combined synergic gene-and immune-therapy against cancer","volume":"8","author":"Nayagom","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: Concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.18632\/oncotarget.24158","article-title":"Endoplasmic reticulum stress stimulates the release of extracellular vesicles carrying danger-associated molecular pattern (DAMP) molecules","volume":"9","author":"Collett","year":"2018","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/febs.13598","article-title":"Cell death induced by endoplasmic reticulum stress","volume":"283","author":"Iurlaro","year":"2016","journal-title":"FEBS J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1566524016666160523143937","article-title":"The Role of the PERK\/eIF2alpha\/ATF4\/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress","volume":"16","author":"Rozpedek","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00109-019-01787-9","article-title":"Regulation and role of the ER stress transcription factor CHOP in alveolar epithelial type-II cells","volume":"97","author":"Klymenko","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3892\/or.2021.7933","article-title":"Endoplasmic reticulum stress, cell death and tumor: Association between endoplasmic reticulum stress and the apoptosis pathway in tumors","volume":"45","author":"Fu","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rapoport, B.L., and Anderson, R. (2019). Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040959"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/kjm2.12375","article-title":"Mechanisms of immunogenic cell death and immune checkpoint blockade therapy","volume":"37","author":"Lin","year":"2021","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","unstructured":"Amjad, M.T., Chidharla, A., and Kasi, A. (2024). Cancer Chemotherapy. StatPearls, StatPearls Publishing."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Xie, D., Wang, Q., and Wu, G. (2022). Research progress in inducing immunogenic cell death of tumor cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017400"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41420-020-0286-z","article-title":"Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: Current opinions and emerging perspectives","volume":"6","author":"Faheem","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer\u2014Role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kumari, R., and Jat, P. (2021). Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.645593"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/ncb1491","article-title":"Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence","volume":"8","author":"Takahashi","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Rovillain, E., Mansfield, L., Lord, C.J., Ashworth, A., and Jat, P.S. (2011). An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence. BMC Genom., 12.","DOI":"10.1186\/1471-2164-12-355"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/1878-0261.13312","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.semcancer.2022.02.005","article-title":"Senescence and the tumor-immune landscape: Implications for cancer immunotherapy","volume":"86","author":"Chibaya","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10522-013-9473-0","article-title":"Immunosurveillance of senescent cells: The bright side of the senescence program","volume":"14","author":"Sagiv","year":"2013","journal-title":"Biogerontology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ouvrier, B., Ismael, S., and Bix, G.J. (2024). Senescence and SASP Are Potential Therapeutic Targets for Ischemic Stroke. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030312"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41232-022-00197-8","article-title":"The roles and mechanisms of senescence-associated secretory phenotype (SASP): Can it be controlled by senolysis?","volume":"42","author":"Ohtani","year":"2022","journal-title":"Inflamm. Regen."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Desprez","year":"2010","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Demirci, D., Dayanc, B., Mazi, F.A., and Senturk, S. (2021). The Jekyll and Hyde of cellular senescence in cancer. Cells, 10.","DOI":"10.3390\/cells10020208"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Cuollo, L., Antonangeli, F., Santoni, A., and Soriani, A. (2020). The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases. Biology, 9.","DOI":"10.3390\/biology9120485"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41586-023-06373-1","article-title":"cGAS\u2013STING drives ageing-related inflammation and neurodegeneration","volume":"620","author":"Gulen","year":"2023","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Schmitz, C.R.R., Maurmann, R.M., Guma, F.T., Bauer, M.E., and Barbe-Tuana, F.M. (2023). cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1132653"},{"key":"ref_66","first-page":"1145","article-title":"The role of cGAS-STING in age-related diseases from mechanisms to therapies","volume":"14","author":"Zheng","year":"2023","journal-title":"Aging Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cas.14266","article-title":"Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer","volume":"111","author":"Loo","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-024-01985-1","article-title":"Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-\u03baB p65 nuclear translocation","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Yang, J., Liu, M., Hong, D., Zeng, M., and Zhang, X. (2021). The paradoxical role of cellular senescence in cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.722205"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djab064","article-title":"Therapy-induced senescence: Opportunities to improve anticancer therapy","volume":"113","author":"Prasanna","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.12688\/f1000research.11671.1","article-title":"Senescence and tumor suppression","volume":"6","author":"Hinds","year":"2017","journal-title":"F1000Research"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Liu, Y., Lomeli, I., and Kron, S.J. (2024). Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?. Cells, 13.","DOI":"10.20944\/preprints202406.0057.v1"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1002\/1878-0261.13042","article-title":"Overcoming the senescence-associated secretory phenotype (SASP): A complex mechanism of resistance in the treatment of cancer","volume":"15","author":"Chambers","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e42886","DOI":"10.1097\/MD.0000000000042886","article-title":"When therapy-induced senescence meets tumors: A double-edged sword: A review","volume":"104","author":"Liu","year":"2025","journal-title":"Medicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1002\/1878-0261.13268","article-title":"Cellular senescence and the tumour microenvironment","volume":"16","author":"Takasugi","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2154115","DOI":"10.1080\/2162402X.2022.2154115","article-title":"Cellular senescence enhances adaptive anticancer immunosurveillance","volume":"12","author":"Marin","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13765-025-01061-2","article-title":"ACF-01 enhances the anticancer effect of doxorubicin by suppressing stemness and inducing apoptosis in triple-negative breast cancer stem-like cells","volume":"68","author":"Yang","year":"2025","journal-title":"Appl. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41514-024-00135-7","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging","volume":"10","author":"Linders","year":"2024","journal-title":"npj Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1703449","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: Chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-021-03736-2","article-title":"B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT\/TM4SF1\/SIRT1 pathway","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1038\/s41388-020-1290-8","article-title":"Correction: Nuclear receptor HNF4alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mad.2008.04.011","article-title":"Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells","volume":"130","author":"Sliwinska","year":"2009","journal-title":"Mech. Ageing Dev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/WNL.63.12_suppl_6.S15","article-title":"Mechanism of action of mitoxantrone","volume":"63","author":"Fox","year":"2004","journal-title":"Neurology"},{"key":"ref_88","first-page":"574","article-title":"Mitoxantrone: A novel anthracycline derivative","volume":"7","author":"Koeller","year":"1988","journal-title":"Clin. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e28473","DOI":"10.4161\/onci.28473","article-title":"Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set","volume":"3","author":"Sukkurwala","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Valanciute, A., Mathieson, L., O\u2019Connor, R.A., Scott, J.I., Vendrell, M., Dorward, D.A., Akram, A.R., and Dhaliwal, K. (2022). Phototherapeutic Induction of Immunogenic Cell Death and CD8+ T Cell-Granzyme B Mediated Cytolysis in Human Lung Cancer Cells and Organoids. Cancers, 14.","DOI":"10.3390\/cancers14174119"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/acel.12518","article-title":"Small molecule compounds that induce cellular senescence","volume":"15","author":"Petrova","year":"2016","journal-title":"Aging Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cyto.a.20983","article-title":"New biomarkers probing depth of cell senescence assessed by laser scanning cytometry","volume":"77","author":"Zhao","year":"2010","journal-title":"Cytom. A"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2019.11.025","article-title":"Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models","volume":"470","author":"Du","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10522-009-9215-5","article-title":"Cyclophosphamide induces premature senescence in normal human fibroblasts by activating MAP kinases","volume":"10","author":"Palaniyappan","year":"2009","journal-title":"Biogerontology"},{"key":"ref_96","first-page":"146","article-title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","volume":"22","author":"Alwahsh","year":"2023","journal-title":"EXCLI J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_98","first-page":"2615","article-title":"Proteasome inhibitors: A novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"38079","DOI":"10.18632\/oncotarget.5752","article-title":"Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells","volume":"6","author":"Ci","year":"2015","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9603271221124094","DOI":"10.1177\/09603271221124094","article-title":"Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening","volume":"41","author":"Wang","year":"2022","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Lu, J., Xu, F., Rao, C., Shen, C., Jin, J., Zhu, Z., Wang, C., and Li, Q. (2022). Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1076958"},{"key":"ref_105","first-page":"2381","article-title":"Curcumin and paclitaxel induce cell death in breast cancer cell lines","volume":"40","author":"Calaf","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Nawara, H.M., Afify, S.M., Hassan, G., Zahra, M.H., Seno, A., and Seno, M. (2021). Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050500"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4\/IKK2\/SNARE-Dependent Exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s11658-021-00287-4","article-title":"Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro","volume":"26","author":"Uruski","year":"2021","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S.A., Basiri, A., and Taheri, M. (2021). 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.658636"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1111\/bph.13725","article-title":"5-fluorouracil causes endothelial cell senescence: Potential protective role of glucagon-like peptide 1","volume":"174","author":"Altieri","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_112","first-page":"945","article-title":"Pulsatilla Decoction Combined with 5-Fluorouracil Triggers Immunogenic Cell Death in Colorectal Cancer Cells","volume":"37","author":"Jie","year":"2022","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-06-2890","article-title":"Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells","volume":"13","author":"Ju","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1021\/bi9006836","article-title":"Novel molecular mechanism for actinomycin D activity as an oncogenic promoter G-quadruplex binder","volume":"48","author":"Kang","year":"2009","journal-title":"Biochemistry"},{"key":"ref_115","first-page":"1904","article-title":"Actinomycin D inhibits cell proliferations and promotes apoptosis in osteosarcoma cells","volume":"8","author":"Lu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e11622","DOI":"10.15252\/emmm.201911622","article-title":"Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress","volume":"12","author":"Humeau","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/2159-8290.CD-21-0177","article-title":"Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy","volume":"11","author":"Wu","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/sj.bjc.6602215","article-title":"Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells","volume":"91","author":"Arango","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3747\/co.v18i1.708","article-title":"Oxaliplatin: A review in the era of molecularly targeted therapy","volume":"18","author":"Alcindor","year":"2011","journal-title":"Curr. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10799893.2019.1655050","article-title":"Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma","volume":"39","author":"Sun","year":"2019","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5114\/ceji.2023.132053","article-title":"Photodynamic therapy augments oxaliplatin-induced immunogenic cell death in colorectal cancer","volume":"48","author":"Wang","year":"2023","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Tomicic, M.T., Kramer, F., Nguyen, A., Schwarzenbach, C., and Christmann, M. (2021). Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14(ARF)-Mediated Sustained p53 Activation. Cancers, 13.","DOI":"10.3390\/cancers13092019"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ko, J.H., Sethi, G., Um, J.Y., Shanmugam, M.K., Arfuso, F., Kumar, A.P., Bishayee, A., and Ahn, K.S. (2017). The Role of Resveratrol in Cancer Therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122589"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","article-title":"Resveratrol for cancer therapy: Challenges and future perspectives","volume":"515","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13765-025-00997-9","article-title":"Resveratrol protects against uremic serum-induced endothelial cell injury by activating the FUS\/KLF2\/FBXW7 signaling pathway","volume":"68","author":"Wang","year":"2025","journal-title":"Appl. Biol. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13027-019-0247-4","article-title":"Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells","volume":"14","author":"Zhang","year":"2019","journal-title":"Infect. Agent. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Kilic Eren, M., Kilincli, A., and Eren, O. (2015). Resveratrol Induced Premature Senescence Is Associated with DNA Damage Mediated SIRT1 and SIRT2 Down-Regulation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124837"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41598-017-00315-4","article-title":"Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"101959","DOI":"10.1016\/j.jddst.2020.101959","article-title":"Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer","volume":"60","author":"Imran","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90148-4","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume":"28","author":"Pienta","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Flieswasser, T., Van Loenhout, J., Freire Boullosa, L., Van den Eynde, A., De Waele, J., Van Audenaerde, J., Lardon, F., Smits, E., Pauwels, P., and Jacobs, J. (2020). Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. Cells, 9.","DOI":"10.3390\/cells9061474"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"12763","DOI":"10.1038\/s41598-023-39880-2","article-title":"IL-1beta is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer","volume":"13","author":"Zhao","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/15353702231179961","article-title":"Wogonin, as a potent anticancer compound: From chemistry to cellular interactions","volume":"248","author":"Tuli","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1038\/cddis.2011.66","article-title":"Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1","volume":"2","author":"Polier","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Yang, Y., Li, X.J., Chen, Z., Zhu, X.X., Wang, J., Zhang, L.B., Qiang, L., Ma, Y.J., Li, Z.Y., and Guo, Q.L. (2012). Wogonin induced calreticulin\/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK\/AKT dependent manner. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050811"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1007\/s00204-020-02842-y","article-title":"Wogonin induces cellular senescence in breast cancer via suppressing TXNRD2 expression","volume":"94","author":"Yang","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/toxres\/tfab107","article-title":"Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment","volume":"10","author":"Wang","year":"2021","journal-title":"Toxicol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"38267","DOI":"10.1038\/srep38267","article-title":"Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species","volume":"6","author":"Liang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"BSR20203834","DOI":"10.1042\/BSR20203834","article-title":"Shikonin inhibits proliferation of melanoma cells by MAPK pathway-mediated induction of apoptosis","volume":"41","author":"Lee","year":"2021","journal-title":"Biosci. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00262-012-1258-9","article-title":"Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine","volume":"61","author":"Chen","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11033-023-09056-2","article-title":"Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation","volume":"51","author":"Chen","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12943-015-0435-9","article-title":"Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components","volume":"14","author":"Lin","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Zheng, H., Huang, Q., Huang, S., Yang, X., Zhu, T., Wang, W., Wang, H., He, S., Ji, L., and Wang, Y. (2018). Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00519"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Liu, W., Zhao, Y., Liu, Q., Wu, D., Li, W., Fu, Z., Yang, L., and Liang, Y. (2024). Systematic bioinformatics analysis reveals the role of shikonin in blocking colon cancer progression by identifying senescence-induced genes. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1360587"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00000421-198704000-00045","article-title":"High-dose chemotherapy. Concepts and strategies","volume":"10","author":"Odaimi","year":"1987","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"38","DOI":"10.17998\/jlc.19.1.38","article-title":"High-dose versus Low-dose 5-Fluorouracil and Cisplatin Based Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma","volume":"19","author":"Lim","year":"2019","journal-title":"J. Liver Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bulcan.2016.08.002","article-title":"High-dose chemotherapy as a strategy to overcome drug resistance in solid tumors","volume":"103","author":"Selle","year":"2016","journal-title":"Bull. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","article-title":"Therapy-induced senescence in cancer","volume":"102","author":"Ewald","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ccr.2008.06.002","article-title":"A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression","volume":"14","author":"Majumder","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0090-4295(00)00538-0","article-title":"Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia","volume":"56","author":"Choi","year":"2000","journal-title":"Urology"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1536\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:43:48Z","timestamp":1789479828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":151,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091536"],"URL":"https:\/\/doi.org\/10.3390\/life16091536","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}